R&D Europe’s growing vector-borne disease threat: Are we keeping... In Europe, diseases once largely associated with tropical or subtropical regions are becoming a more immediate concern.
News argenx agrees Unnatural takeover deal worth up to $1.15bn argenx has agreed its second acquisition of the year, buying macrocyclic peptide drug developer Unnatural Products for $550m upfront.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
